Catalog No.A2009 Synonyms: IDEC-C2B8 Non-humanized mouse model applicable
For research use only. Not for use in humans.
Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
Choose Selective Immunology & Inflammation related Inhibitors
|Description||Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.|
Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. Th strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependentv.
|In vivo||A number of in vivo tumor models suggest the anti-tumor activity of rituximab is dependent, at least in part, on complement. Rituximab can deplete B cells for several months and, as such, could represent an effective therapy for B cell-mediated autoimmune diseases. Rituximab is now widely used in onco-haematology and is currently in development in several autoimmune diseases.|
-  Du J, et al. J Biol Chem. 2007, 282(20):15073-80.
-  George J. Weiner, et al. Semin Hematol. 2010, 47(2): 115-123.
-  Chow KU, et al. Haematologica. 2002, 87(1):33-43.
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
If you have any other enquiries, please leave a message.